-
Mashup Score: 41Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - 21 day(s) ago
Nature – A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15 can…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - 25 day(s) ago
Nature – A study reporting the results of a clinical trial co-administering the GDF-15-blocking antibody visugromab with the anti-PD-1 antibody nivolumab demonstrates that neutralizing GDF-15 can…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Fascinating story behind this! Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours @Nature The neoadjuvant #NeoGDFather trial in MIBC with nivo +/- visugromab is close to end accrual @DrIacovelli https://t.co/XetDkmQTDH
-
-
Mashup Score: 1CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion - 2 year(s) ago
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiating phase 2 development of CTL-
Source: www.businesswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Very much looking forward to expanding Visugromab use as neoadjuvant therapy in #bladdercancer #NeoGDFather @MyUniSR @SanRaffaeleMI CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 https://t.co/xGmAUKi6dv
-
Fascinating story behind this! Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours @Nature The neoadjuvant #NeoGDFather trial in MIBC with nivo +/- visugromab is close to end accrual @DrIacovelli https://t.co/XetDkmQTDH